A
Amita Maheshwari
Researcher at Homi Bhabha National Institute
Publications - 121
Citations - 1509
Amita Maheshwari is an academic researcher from Homi Bhabha National Institute. The author has contributed to research in topics: Cervical cancer & Medicine. The author has an hindex of 17, co-authored 102 publications receiving 999 citations. Previous affiliations of Amita Maheshwari include Tata Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial
Sudeep Gupta,Amita Maheshwari,Pallavi Parab,Umesh Mahantshetty,Rohini Hawaldar,Supriya Chopra,Rajendra Kerkar,Hemant B. Tongaonkar,Jaya Ghosh,Seema Gulia,Neha Kumar,T. Surappa Shylasree,Renuka Gawade,Yogesh Kembhavi,Madhuri Gaikar,Santosh Menon,Meenakshi Thakur,Shyam K. Shrivastava,Rajendra A. Badwe +18 more
TL;DR: Cisplatin-based concomitant chemoradiation resulted in superior DFS compared with neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer.
Journal ArticleDOI
Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shyamkishore Shrivastava,Umesh Mahantshetty,Supriya Chopra,Rohini Hawaldar,Vinod Hande,Rajendra A. Kerkar,Amita Maheshwari,TS Shylasree,Jaya Ghosh,Jyoti Bajpai,Lavanya Gurram,Seema Gulia,Sudeep Gupta +12 more
TL;DR: Chemoradiotherapy using weekly cisplatin chemotherapy results in significantly better DFS and OS compared with RT in women with stage IIIB squamous cell carcinoma of the uterine cervix, providing level 1 evidence in the largest clinical trial reported so far in favor of concurrent weekly cisPlatin chemotherapy in this setting.
Journal ArticleDOI
Gynecological cancers: A summary of published Indian data
TL;DR: A review of the important studies done in India for all gynecological cancers covering all domains such as basic sciences, preventive oncology, pathology, radiological imaging, and clinical outcomes is discussed.
Journal ArticleDOI
Outcomes of Elective Major Cancer Surgery During COVID 19 at Tata Memorial Centre: Implications for Cancer Care Policy.
Shailesh V. Shrikhande,P. S. Pai,Manish S. Bhandare,Ganesh Bakshi,Devendra Chaukar,Pankaj Chaturvedi,Mahesh Goel,Ashish Gulia,Sajid S. Qureshi,Amita Maheshwari,Aliasgar Moiyadi,Sudhir Nair,N. Nair,George Karimundackal,Avanish Saklani,Vinay K. Shankhadhar,V. Parmar,Jigeeshu V Divatia,C.S. Pramesh,Ajay Puri,Rajendra A Badwe +20 more
TL;DR: The results support the continuation of elective major cancer surgery in regions with Covid 19 trends similar to India and a combination of scientific and administrative rationale contributed to favorable outcomes after major elective cancer surgeries.
Journal ArticleDOI
IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells
Ram Kumar Singh,Snehal M. Gaikwad,Ankit Jinager,Smrita Chaudhury,Amita Maheshwari,Pritha Ray +5 more
TL;DR: Findings indicate that a combination of cytotoxic agents and IGF-1R inhibitor is more effective at early stages of chemoresistant ovarian cancer.